Clinical Archive · NA

RepCOPDiPS — iPSC-Based Bronchial Epithelial Repair Model for COPD

Trial ID NCT06755008 ↗
Sponsor University Hospital, Montpellier · France
Cell Source ips · autologous
Indication copd
Phase NA
Status RECRUITING
Delivery Route no patient administration (ex vivo graft model)
Enrollment 50
Publication

Trial Design

RepCOPDiPS involves bronchial biopsies from three groups: patients with COPD, smokers without COPD, and non-smokers without COPD. The harvested cells are reconstituted into an air-liquid interface culture model, after which the ability of an iPSC graft to enhance repair of the damaged bronchial epithelium is assessed. The primary endpoint is the rate of epithelial repair at 24 hours after a scratch injury.

Clinical Significance

Although this is not a treatment trial, it is a mechanistically important study for regenerative medicine development. In a condition as chronic and complex as COPD, validating epithelial repair potential in patient-derived tissue models is a necessary step before clinical application of cell therapies. This study reflects the extension of iPSC-based regenerative approaches into research on pulmonary epithelial injury repair.

Reasons RepCOPDiPS is drawing attention:

  • Patient-derived model — bronchial epithelial cells from actual COPD patients
  • iPSC graft experiment — evaluating the potential to repair damaged epithelium
  • Mechanism-focused research — cytokine profiling, transcriptomics, and cellular composition analysis
  • Translational foundation — providing the preclinical evidence base for future pulmonary regenerative therapy development

Limitations and Discussion

Because this study does not administer iPSC cells to patients, it cannot make direct claims about clinical outcomes. Whether repair effects observed in the ex vivo model are reproducible in living pulmonary tissue requires separate validation. Safety of iPSC cells, differentiation control, and the feasibility of long-term engraftment remain important areas for future investigation.

COPD ips ex-vivo bronchial-epithelium translational